Source news

globenewswire News

20 stories
globenewswire

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) NASDAQ:MNPR, a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) h…

GlobeNewswire en
ETFsStocksUS
globenewswire

Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections

KNOXVILLE, Tenn., June 30, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) OTCQB:PVCT, a clinical-stage biotechnology company developing pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient (“API”) as a platform therapeutic, and…

GlobeNewswire en
StocksUS
globenewswire

Rocket Doctor Enters into a Primary Care Value-Based Care Agreement in the United States, Expanding In-Network Coverage by More Than 5 Million Members

Vancouver, BC, June 30, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE:AIDR, OTC:AIRDF, Frankfurt:939) ("Rocket Doctor AI" or the "Company") today announced that its wholly owned digital health platform and marketplace subsidiary, Rocket Doctor Inc., has entered into its first value-based prim…

GlobeNewswire en
StocksUS
globenewswire

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare disea…

GlobeNewswire en
StocksUS
globenewswire

U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimenPrimary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering CommitteeInterim analysis on primary…

GlobeNewswire en
StocksUS
globenewswire

Eos Energy Announces Updated Terms for Rights Offering

EDISON, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- NASDAQ:EOSE)">Eos Energy Enterprises, Inc. NASDAQ:EOSE ("Eos" or the “Company”), America’s leading innovator in designing, manufacturing, and providing zinc-based long duration energy storage (LDES) systems sourced and manufactured in the United State…

GlobeNewswire en
ETFsStocksUS
globenewswire

Eos Announces Pricing of Registered Direct Offering of Common Stock and Warrants to Fund Investment in Frontier Power USA

EDISON, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. NASDAQ:EOSE (“Eos” or the “Company”) today announced the pricing of a registered direct offering (the “Offering”) to Hudson Bay Capital Management of 13,683,634 shares of our common stock, par value $0.0001 per share, and…

GlobeNewswire en
StocksUS
globenewswire

Almadex Intersects Copper Mineralisation, Expands IP Anomaly at New Hope And Provides Exploration Update

New Hope Project - 598,500E Chargeability Pseudo SectionSelect representative core photos from hole NH-26-002Select representative core photos from hole NH-26-002 (cont.)VANCOUVER, British Columbia, June 30, 2026 (GLOBE NEWSWIRE) -- Almadex Minerals Ltd. (“Almadex” or the “Company”) (TSX-V: “DEX”…

GlobeNewswire en
EconomyStocksUS
globenewswire

Blockfusion and Blue Acquisition Corp. Announce LOIs for Anchor Lease with a Leading AI Customer and $175 Million Convertible Note Financing and Non-Redemption Agreement, and Advancement of Planned Expansion of Niagara Falls Campus

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Blockfusion USA, Inc. (“Blockfusion” or the “Company”), a rapidly growing developer transitioning to become an operator of high performance compute (“HPC”) and AI infrastructure, and Blue Acquisition Corp. (“Blue”) NASDAQ:BACC, a publicly traded special p…

GlobeNewswire en
StocksUS
globenewswire

Brixton Metals Drills 14.75m of 1.25% Copper, 1.71 g/t Gold, 149.0 g/t Silver at the Near Surface Glenfiddich Zone, Camp Creek Corridor

Including 1.50m of 8.33% Copper, 11.30 g/t Gold, 971.0 g/t Silver from 90.00m DepthVANCOUVER, British Columbia, June 30, 2026 (GLOBE NEWSWIRE) -- Brixton Metals Corporation (TSX-V:BBB, OTCQX:BBBXF (the “Company” or “Brixton”) is pleased to announce initial drill results of the 2026 season from its…

GlobeNewswire en
FuturesStocksCA
globenewswire

FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients

FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial PatientsAUSTIN, Texas, June 30, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ NASDAQ:FOCL (the “Company”), the global leader in robotic focal therapy, today announced the laun…

GlobeNewswire en
StocksFRUS
globenewswire

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. NASDAQ:IFRX, a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in…

GlobeNewswire en
StocksDE